[1]Arca P, Reguera G, Hardisson C. 1997. Plasmid-encodedfosfomycin resistance in bacteria isolated from theurinary tract in a multicentre survey. Journal ofAntimicrobial Chemotherapy, 40, 393-399.[2]Baum E Z, Montenegro D A, Licata L, Turchi I, Webb G C,Foleno B, Bush K. 2001. Ident if icat ion andcharacterization of new inhibitors of the Escherichiacoli MurA enzyme. Antimicrobial Agents andChemotherapy, 45, 3182-3188.[3]Brown E D, Vivas E I, Walsh C T, Kolter R. 1995. MurA(MurZ), the enzyme that catalyzes the first committedstep in peptidoglycan biosynthesis, is essential inEscherichia coli. Journal of Bacteriology, 177, 4194-4197.[4]Cassidy P J, Kahan F M. 1973. A stable enzymephosphoenolpyruvateintermediate in the synthesis ofur idine - 5 ´-diphospho-N- a c e tyl -2-amino- 2 -deoxyglucose 3-O-enolpyruvyl ether. Biochemistry, 12,1364-1374.[5]Christensen B G, Leanza W J, Beattie T R, Patchett A A,Arison B H, Ormond R E, Kuehl FA, Albers-SchonbergJr G, Jardetzky O. 1969. Phosphonomycin: structure andsynthesis. Science, 166, 123-125.[6]Du W, Brown J R, Sylvester D R, Huang J, Chalker A F, SoC Y, Holmes D J, Payne D J, Wallis N G. 2000. Twoactive forms of UDP-N-acetylglucosamine enolpyruvyltransferase in Gram-positive bacteria. Journal ofBacteriology, 182, 4146-4152.[7]Garcia-Lobo J M, Ortiz J M. 1982. Tn292l, a transposonencoding fosfomycin resistance. Journal ofBacteriology, 151, 477-479.[8]Hendlin D, Stapley E O, Jackson M , Wallick H, Miller A K,Wolf F J, Miller TW, Chaiet L, Kahan FM, Foltz E L, etal. 1969. Phosphonomycin, a new antibiotic producedby strains of streptomyces. Science, 166, 122-123.[9]Horii T, Kimura T, Sato K, Shibayama K, Ohta M. 1999.Emergence of fosfomycin-resistant isolates of Shigalike toxin-producing Escherichia col i O26 .Antimicrobial Agents and Chemotherapy, 43, 789-793.[10]Jin W J, Zhang Y M, Qin A J, Shao H X, Liu Y L, Wang J,Wang Q Q. 2008. Distribution of virulence-associatedgenes of avian pathogenic Escherichia coli isolates inChina. Agricultural Sciences in China, 7, 1511-1515.[11]Kahan F M, Kahan J S, Cassidy P J, Kropp H. 1974. Themechanism of action of fosfomycin phosphonomycin.Annals of the New York Academy of Sciences, 235,364-386.[12]Lell B, Ruangweerayut R, Wiesner J, Wiesner J, MissinouM A, Schindler A, Baranek T, Hintz M, Hutchinson D,Jomaa H, et al. 2003. Fosmidomycin, a novelchemotherapeutic agent for malaria. AntimicrobialAgents and Chemotherapy, 47, 735-738.[13]Lindgren V, Rutberg L. 1976. Genetic control of the glpsystem in Bacillus subtilis. Journal of Bacteriology,127, 1047-1057.[14]Marquardt J L, Siegele D A, Kolter R , Walsh C T. 1992.Cloning and sequencing of Escherichia coli murZ andpurification of its product, a UDP-N-acetylglucosamineenolpyruvyl transferase. Journal of Bacteriology, 174,5748-5752.[15]McCoy A J, Sandlin R C, Maurelli A T. 2003. In vitro and invivo functional activity of Chlamydia MurA, a UDP-Nacetylglucosamineenolpyruvyl transferase involved inpeptidoglycan synthesis and fosfomycin resistance.Journal of Bacteriology, 185, 1218-1228.[16]Merkel T J, Nelson D M, Brauer C L, Kadner R J. 1992.Promoter elements required for positive control oftranscription of the Escherichia coli uhpT gene.Journal of Bacteriology, 174, 2763-2770.[17]Miller R A, Reimschuessel R. 2006. Epidemiologic cutoffvalues for antimicrobial agents against Aeromonassalmonicida isolates determined by frequencydistributions of minimal inhibitory concentration anddiameter of zone of inhibition data. American Journalof Veterinary Research, 67, 1837-1843.[18]Nilsson A I, Berg O G, Aspevall O, Kahlmeter G, AnderssonD I. 2003. Biological costs and mechanisms offos fomyc in res is t ance in Escher ichia col i .Antimicrobial Agents and Chemotherapy, 47, 2850- 2858.Rao N N, Roberts M F, Torriani A, Yashphe J. 1993. Effectof glpT and glpD mutations on expression of the phoAgene in Escherichia coli. Journal of Bacteriology, 175,74-79.[19]Sambrook J, Russell D W. 2006. The Condensed ProtocolsFrom Molecular Cloning: a Laboratory Manual. ColdSpring Harbor Laboratory Press, Cold Spring Harbor,N.Y.Savini V, Catavitello C, Bianco A, Balbinot A, D’AntonioD. 2009. Epidemiology, pathogenicity and emergingresistances in Staphylococcus pasteuri: from mammalsand lampreys, to man. Recent Patents on Anti-InfectiveDrug Discovery, 4, 123-129.[20]Schito G C, Naber K G, Botto H, Palou J, Mazzei T, GualcoL, MarcheseA. 2009. The ARESC study: an internationalsurvey on the antimicrobial resistance of pathogensinvolved in uncomplicated urinary tract infections.International Journal of Antimicrobial Agents, 34, 407-413.[21]Shimizu M, Shigeobu F, Miyakozawa I, Nakamura A, SuzukiM, Mizukoshi S, O’Hara K, Sawai T. 2000. NovelFosfomycin resistance of Pseudomonas aeruginosaclinical isolates recovered in Japan in 1996.Antimicrobial Agents and Chemotherapy, 44, 2007-2008.[22]Smeyers Y G, Hernandez-Laguna A, von Carstenn-Lichterfelde C. 1983. Quantum mechanical calculationsuseful for determining the mechanism of action offosfomycin. Journal of Pharmaceutical Sciences, 72,1011-1014.[23]Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K,Terada S, Muratani T, Matsumoto T, Nakahama C,Tomono K. 2010. Molecular mechanisms of fosfomycinresistance in clinical isolates of Escherichia coli.International Journal of Antimicrobial Agents, 35, 333-337.[24]Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y.2010. Prevalence of fosfomycin resistance among CTXM-producing Escherichia coli clinical isolates in Japanand identification of novel plasmid-mediatedfosfomycin-modifying enzymes. Antimicrobial Agentsand Chemotherapy, 54, 3061-3064.[25]Wiesner J, Henschker D, Hutchinson D B, Beck E, JomaaH. 2002. In vitro and in vivo synergy of fosmidomycin,a novel antimalarial drug, with clindamycin.Antimicrobial Agents and Chemotherapy, 46, 2889-2894.[26] |